摘要
目的观察厄贝沙坦与辛伐他汀联用对新诊断2型糖尿病(T2DM)患者白蛋白尿和大血管损害的效果。方法101例患者随机分成2组,对照组给予厄贝沙坦及安慰剂;治疗组给予厄贝沙坦及辛伐他汀。观察2组患者不同时期的尿白蛋白排泄率(UAER)、胆固醇(TC)、低密度脂蛋白(LDL-C)、血高敏C反应蛋白(hsCRP)、血肌酐(SCr)的变化,记录大血管损伤表现。结果治疗后2组UAER较治疗前均显著下降,治疗组于治疗24个月后较对照组下降更显著(P<0.05)。治疗组TC、LDL-C、hsCRP均有显著下降(P<0.01),与对照组比较有非常显著差异(P<0.01);2组SCr治疗后均有下降,24个月下降显著(P<0.05)。24个月后治疗组临床DN未增加,与对照组比较差异显著(P<0.05)。24个月后对照组大血管损害的患病率有明显增加(P<0.05);治疗组大血管损害未增加,与对照组比较差异显著(P<0.05)。结论厄贝沙坦及辛伐他汀联用对新诊断T2DM患者减少白蛋白尿、保护肾功能和降低大血管损害有良好效果。
Aim To study the effects of combination therapy of irbesartan and simvastatin in decreasing the urinary albumin excretion rate （UAER） ,protecting the renal function and reducing the risk of cardiovascular damage in newly diagnosed type2diabetic patients. Methods 101 newly diagnosed type 2 diabetic patients were divided randomly into two groups ： the control group was administered with irbesartan ;the treatment group was administered with irbesartan and simvastatin for two years. UAER,TC,LDL - C,hsCRP, SCr were examined immediately and 3,12,24 months after the treatment, and performances of angiopathy were recorded. Results UAER was decreased significantly in two groups. It decreased more significantly in the treatment group than in the control group after 24 months（ P 〈 0.05 ）. TC, DL -C, hsCRP decreased obviously in the treatment group （P 〈 0.01 ）and was differentl from that in the control group（ P 〈 0 01 ）. SCr decreased significantly（ P 〈0.05 ） after 24 months. After 24 months clinical diabetic nephropathies were not increased significantly in the treatment group. Macrovascular damage was increased significantly （ P 〈 0.05 ） in the control group, but was not increased significantly in the treatment after 24 months. Conclusion The combination therapy of irbesartan and simvastatin has good effects in decreasing UAER,in protecting the renal function and in reducing macrovascular damage in newly diagnosed type 2 diabetic patients.
出处
《安徽医药》
CAS
2006年第6期414-416,共3页
Anhui Medical and Pharmaceutical Journal
关键词
糖尿病肾病
大血管损伤
厄贝沙坦和辛伐他汀联用
diabetic nephropathy
macrovascular damage
the combination therapy of irbesartan and simvastatin
